Navigation Links
Intrinsic Bioprobes Announces Issuance of US Patent for Novel Biomarkers and Assays for Myocardial Infarction

TEMPE, Ariz., Oct. 27 /PRNewswire/ -- Intrinsic Bioprobes today announced that the United States Patents and Trademark Office has issued US Patent 7,816,095 covering novel blood protein biomarkers related to cardiovascular disease. This patent is first of a series of patent applications that cover specific human protein variants as biomarkers with clinical utility.

"The biomarkers were discovered using Intrinsic Bioprobes' unique Mass Spectrometric Immunoassay technologies," says Urban Kiernan, Ph.D., the Director of Biomarker Discovery at Intrinsic Bioprobes. These newly identified biomarkers are modified forms of specific circulating blood proteins that, when used in combination, yield exceptional clinical sensitivity and specificity in the determination of myocardial infarction. "We are very excited about these biomarkers because they clearly demonstrate the significance of protein microheterogeneity in human disease, which has been largely unexplored niche in human molecular biology," adds Kiernan.

Intrinsic Bioprobes Inc. (IBI), located in Tempe, AZ, performs unbiased discovery, verification and population studies on full-length proteins, and discovers and defines microheterogeneity in disease-associated biomarker proteins within healthy and disease populations. IBI's principal focus is the development and application of clinical and diagnostic assays and platforms for rapid and sensitive protein biomarker analysis for early detection and efficient treatment of critical human diseases. IBI's advanced technologies are patented and proprietary process platforms and approaches for proteomic and other research and clinical applications that generally leverage advanced mass spectrometry technology. These approaches include IBI's MASSAY(R) technology system, its Mass Spectrometric Immunoassay (MSIA(TM)) technology and its Bioreactive Probes (BRP(TM)). The Company has developed a deep and growing base of intellectual property in its field, consisting of 19 issued patents and numerous pending patent applications.

For more information about Intrinsic Bioprobes Inc., please visit Dobrin NedelkovIntrinsic Bioprobes Inc.Tel. (480) 804-1778E-mail: info@intrinsicbio.comThis press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at

SOURCE Intrinsic Bioprobes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
2. Onyx Pharmaceuticals Announces Third Quarter 2010 Financial Results Teleconference and Webcast
3. Baxa Corporation Announces 2011 Course Schedule for its STAR Center® Training Facility
4. Baltimores Mark E. Spier, DPM, Announces FDA Clearance of PinPointe™ FootLaser™ for Treatment of Nail Fungus
5. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
6. Stereotaxis Announces Third Quarter 2010 Earnings Release Date and Conference Call
7. Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010
8. NCPA Announces Partnership with Live Oak Bank to Help Finance Independent Community Pharmacy Purchases
9. Trius Announces Issuance of Key U.S. Patent for Torezolid Phosphate
10. Tengion Announces First Implantation of Neo-Urinary Conduit™ in Initial Clinical Trial in Patients with Bladder Cancer
11. Roper Industries Announces Record Third Quarter Results
Post Your Comments:
(Date:12/1/2015)... 1, 2015 --> ... Drugs Market by Type of Drug (Monoclonal Antibodies, Interferon-Alpha, Interleukins, ... and Pipeline Analysis - Global Forecast to 2020", published by ... USD 73,529.2 Million by 2020 from USD 40,281.6 Million in ... Browse 37 market data ...
(Date:12/1/2015)... BANGALORE, India and ... (NASDAQ, TASE: MYL) today announced that it expects to ... for developing country markets funded by international donors, TLE400 ... + Efavirenz 400 mg) for $99 per patient, per ... (CHAI) to develop TLE400. The significantly reduced price could ...
(Date:12/1/2015)... 1, 2015  AccuTEC Blades, a leader in ... logo and brand identity program. The new logo ... of bladed products where "the edge makes all ... --> Serving manufacturers and distributors of medical, ... equipment, AccuTEC,s product lines include those acquired when ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Trustify is proud to announce the success ... Becky’s Fund, an organization dedicated to ending domestic violence. , Trustify and Becky’s Fund ... victims and survivors of domestic violence. Trustify is also proud to announce the launch ...
(Date:12/1/2015)... ... December 01, 2015 , ... World Patent Marketing , ... a container patent that allows for easier packing and organizing of items into one ... $90 billion," says Scott Cooper, CEO and Creative Director of World Patent Marketing and ...
(Date:12/1/2015)... ... December 01, 2015 , ... Integrated Rental Services ... Jordan Industries International, LLC (“JII”). , With support from JII, Integrated Rental is ... to hospitals, surgery centers, clinics, research labs and medical facilities across the United ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... of leadless pacemakers in the U.S. and is the only hospital in the ... the largest clinical data presentation of transcatheter pacing patients were revealed recently at ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per workers’ compensation claim ... of hospital and nonhospital care, according to a recent study by the Workers Compensation ... Edition , found medical payments per claim with more than seven days of lost ...
Breaking Medicine News(10 mins):